About Brain Tumors
We believe WP1122 has the potential to target a wide variety of solid tumors, which eventually become resistant to all treatments, and thereby provide a large and important opportunity for novel drugs. Notwithstanding this potential, we are focused on the treatment of central nervous system malignancies and especially glioblastoma. Although less prevalent than some larger categories of solid tumors, cancers of the central nervous system are particularly aggressive and resistant to treatment. The prognosis for such patients can be particularly grim and the treatment options available to their physicians are among the most limited of any cancer.
The National Cancer Institute has estimated 23,130 new cases of brain and other nervous system cancers occurred in the United States in 2013, resulting in 14,080 deaths. Despite the severity and poor prognosis of these tumors, there are few FDA-approved drugs on the market.
We have proof of concept data for WP1122, including data on survival of animals subjected to xenografts of human brain tumors, as well as biodistribution and pharmacokinetics. In non-optimal doses and treatment regimes, WP1122 performed equal to or better than the current market leader, temozolomide, and provided for superior survival for animals treated in combination with temozolomide.